news
Sotorasib plus panitumumab shows efficacy against colorectal cancer
Sotorasib combined with panitumumab displayed 27 percent response rate against colorectal cancer in Phase I/II trial.
List view / Grid view
Biopharmaceuticals
![Moderna COVID-19 vaccine vials [Credit: Giovanni Cancemi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1893225814-300x278.jpg)
![Moderna COVID-19 vaccine vials [Credit: Giovanni Cancemi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1893225814-e1631790550214.jpg)
news
COVID-19 Vaccine Moderna effective against variants of concern
New data shows that Moderna’s COVID-19 vaccine protects against variants of concern and reduces breakthrough infection risk.
news
US government purchases additional 1.4 million doses of REGEN-COV™
Regeneron announced a new US government agreement to purchase additional doses of REGEN-COV (casirivimab and imdevimab) antibody cocktail.
news
J&J’s Ebola vaccine regimen demonstrates immune response
Johnson & Johnson’s Ebola vaccine regimen, Zabdeno® and Mvabea®, generated robust humoral immune responses in adults and children.
news
Viral vector purification market expected to reach over $1 billion by 2028
New research suggests the viral vector purification market will attain a compound annual growth rate of 14.2 percent between 2021 and 2028.
news
Imfinzi™ and tremelimumab combo improves NSCLC outcomes
Imfinizi™ and tremelimumab in combination with chemotherapy improved non-small lung cancer (NSCLC) survival by 23 percent in a Phase III study.
video
Video: Fast BET assay Setup – See it in Action
See how QC analysts can easily set up fully compliant 21-sample BET assays in 9 minutes with less than 30 pipetting steps.
news
Moderna and ILCM to develop Crigler-Najjar syndrome therapeutic
Moderna and the Institute for Life Changing Medicines (ILCM) are collaborating to develop an mRNA therapeutic for Crigler-Najjar syndrome.
news
EMA evaluates data on Comirnaty® COVID-19 vaccine booster dose
EMA begins evaluating the application for a booster dose of Comirnaty® in adults to be given six months after the second dose.
video
Video: Automation of endotoxin assays
Want easy automation of BET assays and high throughput? Watch the video to see fast BET assay setup with centripetal microfluidic automation.
article
Six major disruptors for the generics and biosimilars market
In this article, EPR's Hannah Balfour outlines six factors that could significantly challenge the generics and biosimilars market in the next decade.
news
NMR spectroscopy to enhance biologic drug delivery and stability
Review shows nuclear magnetic resonance (NMR) spectroscopy has the potential to enhance biologic drug formulation, optimising delivery and bioavailability.
news
NICE approves inclisiran for LDL cholesterol reduction
The UK approval follows a Phase III study in which Leqvio® (inclisiran) reduced low-density lipoprotein cholesterol (LDL-C) by 55 percent.
news
Dupixent® reduces atopic dermatitis by 70 percent in Phase III trial
Dupixent is the first biologic medicine to significantly reduce signs and symptoms of atopic dermatitis in children as young as six months.
news
Pharmaceutical membrane filtration market to value $10 billion by 2025
Growth in the global pharmaceutical membrane filtration market will be driven by the increasing adoption of single-use technologies.
